A disruptive therapy
Check out our unprecedented approach in the field of solid cancers.
Learn MoreFrom cancer cell to differentiated cell
Our platform is unique and our approach is unprecedented in the field of solid tissue cancers.
StemGen is a clinical state biotech company developing innovative differentiation biotherapies for cancer.
hrBMP4 gets the Orphan Drug designation by EMA
for the treatment of glioma.
Glioblastoma Multiforme is the most common and aggressive malignant primary brain tumour, considered incurable.
Current standard of care is of limited benefit and prognosis is poor.